Prostate-Specific Antigen (PSA) Testing in Adults

1. Clinical Overview

Summary

Prostate-Specific Antigen (PSA) is a serine protease glycoprotein produced almost exclusively by prostatic epithelial cells. It functions physiologically to liquefy the seminal coagulum, but its clinical utility lies in its role as the most widely used biomarker for prostate cancer screening, detection, and monitoring. While PSA revolutionised prostate cancer detection when introduced in the 1980s, its interpretation requires nuanced clinical judgement due to its organ-specificity rather than cancer-specificity. Elevated PSA levels occur in benign prostatic hyperplasia (BPH), prostatitis, urinary retention, and following prostatic manipulation, as well as in prostate cancer. Modern practice emphasises shared decision-making, using PSA derivatives (free-to-total ratio, PSA density, PSA velocity), age-adjusted reference ranges, and risk calculators to improve diagnostic accuracy and reduce unnecessary biopsies. Major guidelines (USPSTF, EAU, AUA) recommend individualised screening discussions for men aged 55-69 years, balancing the benefits of early cancer detection against the harms of overdiagnosis and overtreatment.

Key Facts

• Definition: PSA is a 33 kDa kallikrein-like serine protease (hK3) produced by prostatic epithelium, encoded by the KLK3 gene on chromosome 19.
• Normal Range: Traditionally less than 4.0 ng/mL, though age-adjusted ranges are preferred (see table below). [1,2]
• Half-life: 2.2-3.2 days in serum. [3]
• Sensitivity for Cancer: ~21% at PSA > 4.0 ng/mL; ~25-35% of men with PSA 4-10 ng/mL have cancer on biopsy. [4]
• Specificity for Cancer: Low (~20-40%) due to elevations in benign conditions. [5]
• Critical Threshold: PSA > 100 ng/mL is highly suggestive of metastatic prostate cancer. [6]
• Screening Target Population: Men aged 55-69 years with > 10-year life expectancy who elect screening after shared decision-making. [7,8]
• Gold Standard Follow-up: Multiparametric MRI (mpMRI) with PIRADS scoring before biopsy for elevated PSA. [9]

Age-Adjusted PSA Reference Ranges

Note: These age-adjusted ranges improve specificity for cancer detection in older men while maintaining sensitivity in younger men where cancer is more aggressive. [2,10]

Clinical Pearls

PSA Organ-Specificity Pearl: PSA is prostate-specific, NOT prostate cancer-specific. Any condition causing prostatic epithelial disruption (BPH, prostatitis, infarction, instrumentation) elevates PSA.

Free-to-Total Ratio Pearl: Cancer cells produce more bound (complexed) PSA. A free-to-total PSA ratio less than 10% suggests ~50% probability of cancer; ratio > 25% suggests ~8% probability. [11]

The "4 ng/mL Myth" Pearl: 15% of men with PSA less than 4.0 ng/mL have prostate cancer on biopsy, and 15% of these are high-grade (Gleason ≥7). There is no "safe" PSA level. [4]

DRE Timing Pearl: Gentle DRE causes minimal PSA elevation (less than 0.4 ng/mL). However, vigorous prostatic massage, biopsy, or cystoscopy can significantly elevate PSA for 2-4 weeks. [12]

Ejaculation Effect Pearl: Ejaculation can transiently elevate PSA by 10-40% for 24-48 hours. Recommend abstinence for 48 hours before PSA testing for optimal accuracy. [13]

5-ARI Effect Pearl: 5-alpha reductase inhibitors (finasteride, dutasteride) approximately halve serum PSA after 6-12 months. DOUBLE the measured PSA value in men on these medications. [14]

PSA Velocity Pearl: PSA velocity > 0.75 ng/mL/year is concerning for cancer, even with PSA in "normal" range. Requires at least 3 measurements over 18-24 months. [15]

Why This Matters Clinically

• Patient Outcomes: Prostate cancer is the second most common male cancer worldwide. Early detection through PSA screening can identify clinically significant cancers when curative treatment is possible, reducing prostate cancer-specific mortality by approximately 20% at 13-year follow-up. [16]
• Overdiagnosis Concern: PSA screening also detects indolent, clinically insignificant cancers that would never cause symptoms or death. The ERSPC trial estimated that 27 men need to be diagnosed to prevent 1 prostate cancer death, highlighting the overdiagnosis problem. [16]
• Treatment Harms: Prostate cancer treatments (radical prostatectomy, radiotherapy) carry significant risks including erectile dysfunction (30-70%), urinary incontinence (5-20%), and bowel dysfunction (5-10%). [17]
• Modern Paradigm: The shift towards mpMRI-targeted biopsy, active surveillance for low-risk cancers, and shared decision-making has improved the benefit-harm ratio of PSA-based screening.
• Exam Relevance: PSA interpretation, screening guidelines, and management of elevated PSA are core topics in MRCP, USMLE, FRACP, and urology specialty examinations.

---

2. Physiology of PSA

Molecular Biology

Gene and Protein:

• PSA is encoded by the KLK3 gene located on chromosome 19q13.4, part of the human kallikrein gene family (15 members).
• It is a 237-amino acid single-chain glycoprotein (33 kDa) with serine protease activity.
• PSA contains one N-linked carbohydrate side chain and belongs to the kallikrein-related peptidase subfamily.

Regulation:

• PSA expression is primarily regulated by androgens (testosterone and dihydrotestosterone) via the androgen receptor (AR).
• The KLK3 gene promoter contains multiple androgen response elements (AREs).
• Androgen deprivation therapy (ADT) suppresses PSA production, forming the basis for PSA monitoring during treatment.

Physiological Function

Normal Role in Seminal Fluid:

• PSA is secreted into prostatic ducts and comprises 0.5-5% of seminal plasma protein.
• Primary function: Liquefaction of the seminal coagulum by cleaving semenogelin I and II (produced by seminal vesicles).
• This releases motile spermatozoa from the coagulum, facilitating fertilisation.
• Normal seminal fluid PSA concentration: 0.5-5 mg/mL (approximately 1 million times higher than serum).

Why PSA Appears in Blood:

• In healthy prostatic tissue, PSA is secreted apically into prostatic ducts and does not enter systemic circulation.
• Disruption of prostatic basement membrane or basal cell layer allows PSA to leak into the bloodstream.
• In prostate cancer, architectural disruption and loss of basal cells increase PSA leakage relative to PSA production.

PSA Forms in Serum

The Free-to-Total PSA Ratio:

• Prostate cancer cells preferentially release complexed PSA.
• BPH releases more free PSA.
• Clinical utility: A low free-to-total ratio (less than 10-15%) suggests higher cancer probability and supports proceeding to biopsy. [11]

PSA Kinetics

---

3. Factors Affecting PSA Levels

Causes of Elevated PSA

Understanding factors that elevate PSA is crucial for accurate interpretation and avoiding unnecessary investigations.

Malignant Causes:

Benign Causes:

Iatrogenic Causes:

Causes of Decreased PSA

Pre-analytical Considerations

Optimal Conditions for PSA Testing:

1. Abstain from ejaculation for 48 hours before testing
2. Avoid vigorous cycling for 24-48 hours
3. Delay testing 6 weeks after prostate biopsy or acute prostatitis
4. Document 5-ARI use and adjust interpretation accordingly
5. Confirm absence of active UTI before testing
6. DRE can be performed before PSA blood draw (minimal effect)

---

4. PSA Derivatives and Risk Calculators

Free-to-Total PSA Ratio (f/t PSA)

Rationale:

• Prostate cancer cells produce more alpha-1-antichymotrypsin-bound PSA.
• BPH produces more free (unbound) PSA.
• The ratio helps discriminate cancer from benign causes in the "grey zone" (PSA 4-10 ng/mL).

Interpretation:

Limitations:

• Only validated for PSA 4-10 ng/mL
• Less useful in PSA less than 4 or > 10 ng/mL
• Requires same assay for total and free PSA
• BPH volume can still cause low ratios

PSA Density (PSAD)

Calculation: PSAD = Total PSA (ng/mL) ÷ Prostate Volume (mL)

Clinical Utility:

• Normalises PSA for prostate size
• Particularly useful in men with large prostates (> 40 mL) and modest PSA elevation
• PSAD > 0.15 ng/mL/cc suggests higher probability of clinically significant cancer [19]
• Now incorporated into MRI-guided biopsy decision algorithms

PSA Velocity (PSAV)

Calculation: PSAV = (PSA₂ - PSA₁) ÷ Time interval (years)

Requirements:

• At least 3 PSA measurements
• Minimum 18-24 month interval
• Same laboratory/assay method preferred

Interpretation:

• PSAV > 0.75 ng/mL/year is concerning for prostate cancer, even with PSA less than 4 ng/mL [15]
• PSAV > 2.0 ng/mL/year strongly associated with aggressive cancer
• Most useful in men undergoing surveillance (active surveillance or post-treatment monitoring)

PSA Doubling Time (PSADT)

Calculation: PSADT = (Time interval × ln2) ÷ ln(PSA₂/PSA₁)

Clinical Application:

• Primarily used for monitoring after definitive treatment
• PSADT less than 3 months: Aggressive disease, consider systemic therapy
• PSADT 3-12 months: Intermediate; consider salvage local therapy
• PSADT > 12 months: Indolent disease; may observe

Prostate Health Index (PHI)

Components:

• Total PSA
• Free PSA
• [-2]proPSA (a truncated pro-form of PSA)

Formula: PHI = ([-2]proPSA / free PSA) × √total PSA

Interpretation:

Advantages:

• FDA-approved for men with PSA 4-10 ng/mL and negative DRE
• Improves specificity over total PSA alone
• Outperforms free-to-total ratio in head-to-head studies [22]

4Kscore Test

Components:

• Total PSA
• Free PSA
• Intact PSA
• Human Kallikrein 2 (hK2)
• Plus: Age, DRE findings, prior biopsy status

Output:

• Percentage probability of high-grade (Gleason ≥7) prostate cancer on biopsy

Clinical Utility:

• Predicts aggressive cancer specifically
• May reduce unnecessary biopsies by 30-50%
• Available commercially

Multiparametric MRI Integration

Current Best Practice: MRI-first pathway before biopsy for elevated PSA:

1. PSA elevated or rising
2. Multiparametric MRI (mpMRI) with PIRADS scoring
3. PIRADS 1-2: Consider observation (cancer unlikely)
4. PIRADS 3: Consider clinical risk factors; MRI-targeted biopsy if high-risk
5. PIRADS 4-5: MRI-targeted biopsy recommended

Evidence:

• PRECISION trial: MRI-targeted biopsy detected 38% more clinically significant cancers and 26% fewer insignificant cancers compared to TRUS-guided biopsy. [9]

---

5. Prostate Cancer Screening Guidelines

Overview of Major Guidelines

Understanding the evidence and guideline differences is essential for clinical practice and examinations.

USPSTF Evidence Summary (2018)

Benefits of PSA Screening:

• Reduction in prostate cancer-specific mortality of approximately 1.3 deaths per 1,000 men screened over 13 years (ERSPC data) [16]
• Prevents metastatic disease: 3.1 fewer metastatic cancers per 1,000 men screened
• Earlier stage at diagnosis

Harms of PSA Screening:

• Overdiagnosis: 20-50% of screen-detected cancers would never cause symptoms
• Overtreatment: Many men treated for indolent cancers suffer treatment complications
• False positives: ~12% positive PSA tests; 75% of these men do not have cancer on biopsy
• Biopsy complications: 1-6% hospitalisation rate; sepsis, bleeding, urinary retention
• Anxiety: Psychological burden of elevated PSA and waiting for results

EAU Risk-Adapted Screening Strategy

Baseline PSA at Age 45-50:

• Risk stratification based on initial PSA level
• Guides screening interval:

High-Risk Populations

Earlier or More Intensive Screening Considered For:

When to Stop Screening

Screening Discontinuation:

• Men with less than 10-15 year life expectancy
• Men > 70-75 years with consistently low PSA (less than 3 ng/mL)
• Men who choose to stop after informed discussion
• After diagnosis and treatment completion (transition to surveillance)

---

6. Clinical Approach to Elevated PSA

Initial Evaluation Algorithm

                  ELEVATED PSA DETECTED
                          |
                          v
     +--------------------------------------------+
     |     STEP 1: CONFIRM AND CONTEXTUALISE      |
     |  - Repeat PSA in 4-6 weeks (same lab)      |
     |  - Review pre-analytical factors           |
     |  - Check for UTI, recent ejaculation       |
     |  - Review medications (5-ARIs)             |
     +--------------------------------------------+
                          |
          PSA Persistently Elevated
                          |
                          v
     +--------------------------------------------+
     |     STEP 2: CLINICAL ASSESSMENT            |
     |  - Digital Rectal Examination (DRE)        |
     |  - Lower urinary tract symptoms (IPSS)     |
     |  - Family history assessment               |
     |  - Life expectancy estimation              |
     +--------------------------------------------+
                          |
                          v
     +--------------------------------------------+
     |     STEP 3: RISK STRATIFICATION            |
     |  - Free-to-total PSA ratio                 |
     |  - PSA density (if volume known)           |
     |  - Consider PHI or 4Kscore                 |
     |  - Apply risk calculator                   |
     +--------------------------------------------+
                          |
              High Risk          Low-Intermediate Risk
                  |                       |
                  v                       v
     +-----------------------+   +-----------------------+
     |   STEP 4A: mpMRI      |   |   STEP 4B: Discuss    |
     |   PIRADS scoring      |   |   Options with patient|
     +-----------------------+   |   - Observation       |
              |                  |   - Repeat PSA 3-6mo  |
              v                  |   - Consider MRI      |
     PIRADS 1-2: Observe         +-----------------------+
     PIRADS 3-5: Targeted Biopsy

Interpreting the DRE

Normal Findings:

• Smooth, symmetrical, firm but elastic consistency
• Median sulcus palpable
• Approximate size of walnut (20-25 mL)

Abnormal Findings Concerning for Cancer:

Benign Findings:

• Diffuse enlargement (BPH)
• Boggy, tender prostate (prostatitis)
• Soft, smooth enlargement

When to Refer to Urology

Urgent Referral (2-Week Wait Cancer Pathway):

• PSA above age-adjusted threshold with suspicious DRE
• PSA > 20 ng/mL
• Rapid PSA rise (velocity > 2 ng/mL/year)
• Clinical features of metastatic disease (bone pain, spinal cord symptoms)

Routine Referral:

• Persistently elevated PSA requiring further investigation
• Patient preference for urological assessment
• Consideration of MRI-guided biopsy

---

7. PSA in Different Clinical Contexts

PSA in BPH

• BPH causes PSA elevation proportional to prostate size (~0.3 ng/mL per gram of BPH tissue)
• Large prostates (> 50 mL) commonly have PSA 4-10 ng/mL without cancer
• PSA density less than 0.10-0.15 ng/mL/cc suggests BPH rather than cancer
• 5-ARI treatment reduces PSA by ~50%; failure to decline suggests possible cancer

PSA in Prostatitis

Acute Bacterial Prostatitis:

• PSA can rise dramatically (> 10-20 ng/mL)
• Repeat PSA 6-8 weeks after treatment completion
• Persistent elevation requires further investigation

Chronic Prostatitis/CPPS:

• May cause modest, fluctuating PSA elevation
• Serial measurements help distinguish from cancer
• Free-to-total ratio often preserved (> 20%)

PSA After Definitive Treatment

Post-Radical Prostatectomy:

• PSA should become undetectable (less than 0.1 ng/mL) within 4-6 weeks
• Biochemical Recurrence (BCR): PSA ≥0.2 ng/mL on two occasions [18]
• PSADT less than 3 months suggests systemic disease; > 12 months suggests local recurrence

Post-Radiation Therapy:

• PSA declines gradually over 12-24 months to nadir
• Phoenix Definition of BCR: PSA nadir + 2.0 ng/mL [23]
• "PSA bounce" (transient rise of 0.1-0.5 ng/mL) is common and benign

PSA During Androgen Deprivation Therapy

• Rapid PSA decline expected within 3-6 months
• Undetectable PSA is associated with better prognosis
• Rising PSA on ADT defines Castration-Resistant Prostate Cancer (CRPC)
• CRPC requires serum testosterone less than 50 ng/dL (less than 1.7 nmol/L)

PSA for Active Surveillance

Eligibility (Low-Risk Cancer):

• Gleason 3+3=6 (Grade Group 1)
• PSA less than 10 ng/mL
• Clinical stage T1c-T2a
• ≤2 positive cores, ≤50% core involvement

Monitoring Protocol:

• PSA every 3-6 months
• DRE every 6-12 months
• Repeat mpMRI at 12 months, then periodically
• Repeat biopsy at 12 months, then as indicated

Triggers for Treatment Consideration:

• PSA velocity > 0.75-1.0 ng/mL/year
• Grade progression on biopsy (Gleason ≥7)
• Increased tumour volume on MRI or biopsy
• Patient preference

---

8. Shared Decision-Making Framework

Elements of Informed Discussion

Before Offering PSA Testing:

1. Explain Purpose

   • PSA is a blood test to help detect prostate cancer early
   • Does not diagnose cancer directly; may lead to further tests

2. Discuss Potential Benefits

   • May detect cancer at an early, curable stage
   • Reduces risk of dying from prostate cancer
   • Prevents metastatic disease in some men

3. Discuss Potential Harms

   • Most men with elevated PSA do NOT have cancer
   • May lead to anxiety and further invasive tests (biopsy)
   • Risk of diagnosing cancers that would never cause harm
   • Treatments can cause erectile dysfunction, incontinence

4. Acknowledge Uncertainty

   • PSA screening is controversial among experts
   • Benefits are modest at the population level
   • Individual values and preferences matter

5. Assess Patient Values

   • How does patient feel about uncertainty?
   • Would they rather "know" even if it leads to difficult decisions?
   • How would they cope with treatment side effects?

Decision Aids

Several validated decision aids are available:

• NHS Prostate Cancer Risk Management Programme materials
• USPSTF Prostate Cancer Screening Information
• AUA Shared Decision-Making Resources

---

9. Complications and Limitations

Limitations of PSA Testing

Biopsy-Related Complications

Note: Transperineal biopsy has largely replaced transrectal (TRUS) biopsy in many centres due to dramatically reduced sepsis risk.

---

10. Evidence and Guidelines

Landmark Trials

1. ERSPC (European Randomized Study of Screening for Prostate Cancer) [16]

• Design: RCT, 182,000 men aged 50-74 across 8 European countries
• Intervention: PSA screening every 2-4 years vs. no screening
• Follow-up: 16+ years
• Results:
  • 20% relative reduction in prostate cancer mortality (RR 0.80, 95% CI 0.72-0.89)
  • Number needed to invite (NNI) = 570; Number needed to diagnose (NND) = 18 to prevent 1 death
• Conclusion: PSA screening reduces prostate cancer mortality, but with significant overdiagnosis

2. PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) [24]

• Design: RCT, 76,685 men aged 55-74 in United States
• Results: No significant mortality benefit (contamination of control arm was high - ~80% had PSA testing)
• Limitation: High control arm screening rates compromise validity

3. PIVOT (Prostate Cancer Intervention Versus Observation Trial) [25]

• Design: RCT, 731 men with localised prostate cancer
• Intervention: Radical prostatectomy vs. observation
• Results: No overall mortality difference; surgery reduced mortality in intermediate-risk disease
• Conclusion: Supports active surveillance for low-risk disease

4. ProtecT (Prostate Testing for Cancer and Treatment) [17]

• Design: RCT, 1,643 men with localised prostate cancer
• Intervention: Active monitoring vs. surgery vs. radiotherapy
• Results at 10 years:
  • Prostate cancer mortality low in all groups (~1%)
  • Surgery/RT reduced metastases compared to monitoring
  • "Surgery: 5-fold higher incontinence; RT: more bowel symptoms"
• Conclusion: Informs shared decision-making about treatment options

5. PRECISION Trial [9]

• Design: RCT, 500 men with clinical suspicion of prostate cancer
• Intervention: mpMRI-targeted biopsy vs. standard TRUS biopsy
• Results:
  • "MRI-targeted: 38% more clinically significant cancers detected"
  • "MRI-targeted: 26% fewer insignificant cancers detected"
  • 28% of men in MRI arm avoided biopsy (negative MRI)
• Conclusion: MRI-first pathway is superior; now standard of care

Key Guidelines Summary

---

11. Prognosis and Follow-up

Prognosis by PSA Level at Diagnosis

PSA Response Thresholds

After Radical Prostatectomy:

• Undetectable PSA (less than 0.1 ng/mL): Excellent prognosis
• BCR (≥0.2 ng/mL): 10-year metastasis-free survival ~75% without salvage therapy

After Radiation:

• Nadir PSA less than 0.5 ng/mL: Excellent prognosis
• Higher nadir correlates with higher recurrence risk

On ADT for Advanced Disease:

• PSA nadir less than 0.2 ng/mL: Median survival > 75 months
• PSA nadir > 4 ng/mL: Median survival ~30 months

---

12. Patient Explanation

What is PSA?

PSA stands for Prostate-Specific Antigen. It is a protein produced by your prostate gland, a small organ below your bladder that is part of the reproductive system. A small amount of PSA normally leaks into your blood, and we can measure this with a simple blood test.

Why is PSA Testing Done?

PSA testing is used to:

1. Screen for prostate cancer - PSA levels tend to be higher in men with prostate cancer, so testing may help detect cancer early when treatment is most effective.
2. Monitor known prostate conditions - If you have prostate cancer, BPH, or prostatitis, PSA levels help track how well treatment is working.

What Do the Results Mean?

• Lower PSA (e.g., less than 2 ng/mL): Low probability of prostate cancer, but not zero. Repeat testing may be recommended.
• Grey zone PSA (4-10 ng/mL): About 25-30% of men in this range have cancer. Further tests like MRI or additional blood tests may help clarify the risk.
• Higher PSA (> 10 ng/mL): Higher probability of cancer, but can also occur with large benign prostate enlargement or infection.

Important Points to Understand

1. An elevated PSA does not mean you have cancer - Many conditions cause high PSA, including benign prostate enlargement and inflammation.
2. A normal PSA does not guarantee you are cancer-free - Some cancers exist with low PSA levels.
3. Screening has benefits and harms - It may save lives by finding cancer early, but it may also lead to unnecessary tests and treatment for cancers that would never cause problems.

Questions to Consider Before Testing

• How would I feel about having more tests if my PSA is elevated?
• If prostate cancer were found, would I want treatment knowing the potential side effects?
• What are my personal values about knowing versus not knowing?

---

13. Examination Focus

Viva Points

"PSA is a serine protease produced by prostatic epithelium, encoded by KLK3. It is prostate-specific but NOT cancer-specific. The traditional threshold of 4 ng/mL is now considered oversimplistic; age-adjusted ranges and PSA derivatives (free-to-total ratio, PSA density, velocity) improve specificity. Major guidelines recommend shared decision-making for screening in men aged 55-69 with > 10-year life expectancy. The MRI-first pathway (PRECISION trial) is now standard before biopsy. Key factors affecting PSA include BPH, prostatitis, ejaculation, and 5-ARIs (which halve PSA)."

Common Examination Questions

Q: What is the significance of a PSA of 6 ng/mL in a 55-year-old man? A: This is above the age-adjusted threshold (3.5 ng/mL for 50-59 years). Approximately 25-30% chance of cancer. Recommend repeat PSA, DRE, free-to-total ratio, and consider mpMRI before biopsy decision.

Q: A patient on finasteride has PSA of 3 ng/mL. How do you interpret this? A: 5-ARIs reduce PSA by ~50%. The "true" PSA is approximately 6 ng/mL. This requires further investigation as for any elevated PSA.

Q: What is PSA velocity, and what is concerning? A: PSA velocity is the rate of PSA change over time. > 0.75 ng/mL/year is concerning for cancer, even with PSA in "normal" range. Requires at least 3 measurements over 18-24 months.

Q: A patient has PSA 8 ng/mL with free-to-total ratio of 28%. What does this suggest? A: High free-to-total ratio (> 25%) suggests ~8-10% cancer probability. This favours BPH over cancer. Could consider observation with repeat PSA in 3-6 months or mpMRI rather than immediate biopsy.

Key Examination Points

• Know age-adjusted PSA reference ranges
• Understand factors that raise and lower PSA
• Be able to interpret free-to-total ratio
• Know USPSTF Grade C recommendation and rationale
• Understand MRI-first pathway (PRECISION trial)
• Know definitions of biochemical recurrence (post-surgery: ≥0.2 ng/mL; post-RT: nadir + 2 ng/mL)
• Explain shared decision-making framework

Common Mistakes

• Assuming PSA > 4 = cancer: Remember 70-75% of men with PSA 4-10 do NOT have cancer
• Ignoring age-adjusted ranges: A PSA of 5 ng/mL is more significant in a 50-year-old than a 75-year-old
• Forgetting 5-ARI effect: Always double PSA in men on finasteride/dutasteride
• Recommending immediate biopsy for elevated PSA: MRI-first pathway is now standard
• Not discussing screening limitations: Shared decision-making is essential
• Interpreting single PSA: Always confirm with repeat testing before intervention

---

14. References

1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-1161. PMID: 1707140 doi:10.1056/NEJM199104253241702

2. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270(7):860-864. PMID: 7688054 doi:10.1001/jama.1993.03510070082041

3. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-916. PMID: 2442609 doi:10.1056/NEJM198710083171501

4. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246. PMID: 15163773 doi:10.1056/NEJMoa031918

5. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98. PMID: 20200110 doi:10.3322/caac.20066

6. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991;145(2):313-318. PMID: 1703243 doi:10.1016/s0022-5347(17)38320-6

7. US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. PMID: 29801017 doi:10.1001/jama.2018.3710

8. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2024 Update. Eur Urol. 2024;85(2):79-126. PMID: 38041302 doi:10.1016/j.eururo.2023.11.002

9. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION). N Engl J Med. 2018;378(19):1767-1777. PMID: 29552975 doi:10.1056/NEJMoa1801993

10. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996;335(5):304-310. PMID: 8663869 doi:10.1056/NEJM199608013350502

11. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547. PMID: 9605898 doi:10.1001/jama.279.19.1542

12. Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA. 1992;267(16):2227-2228. PMID: 1372943 doi:10.1001/jama.1992.03480160073034

13. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997;50(2):239-243. PMID: 9255295 doi:10.1016/S0090-4295(97)00233-3

14. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Urology. 1998;52(2):195-201. PMID: 9697781 doi:10.1016/s0090-4295(98)00184-8

15. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98(21):1521-1527. PMID: 17077355 doi:10.1093/jnci/djj410

16. Hugosson J, Roobol MJ, Bjartell A, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med. 2019;381(4):338-349. PMID: 31330826 doi:10.1056/NEJMoa1804593

17. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer (ProtecT). N Engl J Med. 2016;375(15):1415-1424. PMID: 27626136 doi:10.1056/NEJMoa1606220

18. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540-545. PMID: 17222629 doi:10.1016/j.juro.2006.10.097

19. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147(3 Pt 2):815-816. PMID: 1371554 doi:10.1016/s0022-5347(17)37393-7

20. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-589. PMID: 10096388 doi:10.1016/s0090-4295(98)00655-4

---

15. Novel and Emerging Biomarkers

Beyond PSA: Improving Risk Stratification

While PSA remains the cornerstone of prostate cancer detection, its limitations have driven development of complementary biomarkers.

Blood-Based Biomarkers

Urine-Based Biomarkers

Tissue-Based Biomarkers

Imaging Advances

PSMA PET/CT:

• Prostate-Specific Membrane Antigen is highly expressed on prostate cancer cells
• PSMA PET/CT (e.g., Ga-68 PSMA-11, F-18 piflufolastat) revolutionised staging
• Superior sensitivity for detecting metastases compared to conventional imaging
• Now standard for staging high-risk disease and BCR workup

Future Directions

1. Liquid Biopsy: Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) for monitoring
2. MRI-Derived Biomarkers: AI-enhanced PIRADS scoring and radiomics
3. Multi-marker Panels: Combining blood, urine, and genetic markers
4. Risk Prediction Models: Machine learning integration of clinical, imaging, and biomarker data

---

16. Special Populations

PSA in Younger Men (Age less than 55 years)

Clinical Considerations:

• Prostate cancer in younger men often more aggressive
• BRCA2 carriers: 8.6-fold increased risk of prostate cancer
• Baseline PSA at age 40-45 recommended for high-risk individuals
• Lower PSA thresholds may be appropriate (e.g., PSA > 1.5 ng/mL at age 40-49 warrants surveillance)

Hereditary Prostate Cancer:

• BRCA1/2, HOXB13, Lynch syndrome (MLH1, MSH2, MSH6, PMS2)
• Earlier screening (age 40) and more intensive follow-up
• Genetic counselling for men with strong family history

PSA in Older Men (Age > 70 years)

Considerations:

• Higher baseline PSA expected (age-adjusted threshold: 6.5 ng/mL)
• Life expectancy assessment crucial (screen if > 10-15 years)
• Competing mortality risks may outweigh cancer-specific mortality
• Active surveillance more often appropriate even for intermediate-risk cancers
• De-escalation of screening in men > 75 with low PSA history

PSA in Men of African Ancestry

Key Points:

• 60% higher prostate cancer incidence than Caucasian men
• 2-3 times higher mortality rate
• Earlier age at presentation
• May have lower PSA thresholds for cancer detection
• AUA/NCCN recommend earlier screening discussions (age 40-45)
• Cultural and healthcare access factors compound biological differences

PSA in Transgender Patients

Male-to-Female (Trans Women):

• Oestrogen therapy suppresses PSA production
• Prostate remains (unless surgically removed)
• Very low PSA expected on hormone therapy
• Any detectable PSA may warrant investigation
• Screening recommendations unclear; individualise

Female-to-Male (Trans Men):

• No prostate; PSA testing not applicable

PSA in Men with Chronic Kidney Disease

• PSA clearance may be affected by renal function
• Limited data on reference ranges in CKD
• Consider clinical context and trend rather than absolute values
• Haemodialysis does not significantly alter PSA

---

17. Medico-legal Considerations

Documentation Requirements

When discussing PSA testing, document:

1. That shared decision-making discussion occurred
2. Benefits and harms were explained
3. Patient's informed choice (testing or declining)
4. Plan for follow-up if testing performed

Common Litigation Scenarios

Informed Consent Considerations

For PSA testing:

• No formal written consent typically required for blood test
• However, verbal informed consent and documentation essential
• Decision aids recommended by USPSTF

For prostate biopsy:

• Written informed consent required
• Explain alternatives (MRI, surveillance)
• Document discussion of complications (infection, bleeding, ED, incontinence)

---

18. Clinical Practice MCQs

Question 1

A 62-year-old man has a PSA of 5.8 ng/mL on routine screening. DRE is normal. He takes finasteride 5 mg daily for BPH. What is the most appropriate next step?

A. Reassure - PSA is within normal limits for his age B. Calculate the "true" PSA as approximately 11.6 ng/mL and refer urgently C. Repeat PSA in 12 months D. Arrange immediate TRUS-guided prostate biopsy E. Stop finasteride and recheck PSA in 3 months

Answer: B

Explanation: 5-alpha reductase inhibitors (finasteride, dutasteride) reduce PSA by approximately 50% after 6-12 months of use. The measured PSA of 5.8 ng/mL should be doubled to ~11.6 ng/mL to estimate the "true" PSA. This significantly elevated value warrants urgent urological referral for further investigation including mpMRI.

---

Question 2

A 58-year-old man with no urinary symptoms has three PSA measurements over 2 years: 2.1 → 2.8 → 3.6 ng/mL. DRE is normal. Free-to-total PSA ratio is 22%. What is the most concerning finding?

A. PSA > 3.5 ng/mL (above age-adjusted threshold) B. PSA velocity of 0.75 ng/mL/year C. Free-to-total ratio of 22% D. Normal DRE despite rising PSA E. Absence of LUTS

Answer: B

Explanation: PSA velocity is (3.6 - 2.1) ÷ 2 years = 0.75 ng/mL/year, which is at the threshold for concern regardless of absolute PSA value. This rate of rise suggests possible cancer even with PSA below 4 ng/mL. The free-to-total ratio of 22% is actually reassuring (higher ratios suggest BPH). Further investigation with mpMRI is warranted.

---

Question 3

Which of the following is TRUE regarding the PRECISION trial?

A. It demonstrated that TRUS biopsy detects more clinically significant cancers than MRI-targeted biopsy B. MRI-targeted biopsy detected 26% fewer clinically insignificant cancers C. All men with negative MRI required systematic biopsy D. MRI increased the total number of biopsies performed E. The trial was conducted only in men with prior negative biopsy

Answer: B

Explanation: The PRECISION trial (NEJM 2018) compared mpMRI with MRI-targeted biopsy vs. standard TRUS-guided systematic biopsy in biopsy-naive men. Key findings: MRI-targeted biopsy detected 38% MORE clinically significant cancers and 26% FEWER clinically insignificant cancers. Additionally, 28% of men in the MRI arm avoided biopsy entirely due to negative MRI findings.

---

Question 4

A 70-year-old man underwent radical prostatectomy for Gleason 4+3=7 prostate cancer 2 years ago. His PSA was undetectable post-operatively. Recent PSA: 0.15 ng/mL, now 0.25 ng/mL (6 weeks later). What is the diagnosis?

A. PSA bounce - observation only B. Biochemical recurrence - requires immediate treatment C. Biochemical recurrence - further investigations needed before treatment D. Laboratory error - repeat PSA E. Prostatic bed inflammation

Answer: C

Explanation: Biochemical recurrence (BCR) after radical prostatectomy is defined as PSA ≥0.2 ng/mL confirmed on a second measurement. This patient meets the definition with PSA 0.25 ng/mL. However, BCR does not mandate immediate treatment. PSA doubling time, imaging (PSMA PET), and risk stratification inform whether salvage radiotherapy, observation, or systemic therapy is appropriate.

---

Question 5

Regarding PSA physiology, which statement is CORRECT?

A. PSA is exclusively produced by prostate cancer cells B. Serum PSA levels are typically 1000 times lower than seminal fluid levels C. PSA is primarily cleared by the spleen D. The half-life of PSA in serum is approximately 12-24 hours E. Free PSA is the predominant form in the serum of patients with prostate cancer

Answer: B

Explanation: PSA in seminal fluid is 0.5-5 mg/mL compared to 0-4 ng/mL in serum - approximately 1,000,000 times higher (option B understates this but is closest to correct among the options). PSA is produced by normal and benign prostatic epithelium as well as cancer cells (A is wrong). PSA half-life is 2.2-3.2 days, not hours (D is wrong). In prostate cancer, complexed (bound) PSA predominates, not free PSA (E is wrong).

---

Question 6

A patient asks about PSA screening. According to USPSTF 2018 guidelines, which statement is most accurate?

A. All men aged 55-69 should have annual PSA testing B. PSA screening is not recommended for any age group C. Individualised decision-making is recommended for men aged 55-69 D. Men over 70 should continue screening if healthy E. Baseline PSA at age 40 is mandatory for all men

Answer: C

Explanation: The USPSTF 2018 guidelines give a Grade C recommendation for men aged 55-69 years, meaning that clinicians should offer PSA screening selectively based on professional judgement and patient preferences, with shared decision-making. The decision should be individualised. Grade D (against) is given for men ≥70 years. No mandatory baseline testing is specified.

---

19. Key Points Summary

Essential Knowledge Points

1. PSA is prostate-specific, NOT cancer-specific - BPH, prostatitis, ejaculation, and instrumentation all elevate PSA

2. Age-adjusted thresholds improve specificity:

   • 40-49: 2.5 ng/mL
   • 50-59: 3.5 ng/mL
   • 60-69: 4.5 ng/mL
   • 70-79: 6.5 ng/mL

3. 5-ARI effect: Finasteride/dutasteride halve PSA - DOUBLE the measured value

4. Free-to-total ratio: less than 10% suggests ~50% cancer probability; > 25% suggests ~8%

5. PSA velocity: > 0.75 ng/mL/year concerning for cancer, even with "normal" PSA

6. MRI-first pathway: PRECISION trial showed MRI-targeted biopsy detects more significant cancers and fewer insignificant cancers

7. Shared decision-making: USPSTF Grade C for ages 55-69 - discuss benefits and harms

8. BCR definitions:

   • Post-prostatectomy: ≥0.2 ng/mL
   • Post-radiotherapy: Nadir + 2.0 ng/mL

9. PSA > 100 ng/mL: Strongly suggests metastatic disease (> 95% PPV for bone mets)

10. Active surveillance monitoring: PSA every 3-6 months; velocity > 0.75-1.0 ng/mL/year triggers reassessment

---

20. Quick Reference Card

PSA Quick Facts

Critical Actions

• Repeat elevated PSA before invasive investigation
• Document 5-ARI use and adjust interpretation
• Consider MRI before biopsy (PRECISION standard of care)
• Shared decision-making before any screening PSA
• Age and life expectancy guide screening intensity

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team